US FDA approves Ipsen's SohonosTM (palovarotene) capsules,
Breakthrough treatment reduces new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, fibrodysplasia...
Source: globenewswire.com
Franchise Communications News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Franchise Communications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Franchise Communications Today - Breaking & Trending Today
US FDA approves Ipsen's SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva
Breakthrough treatment reduces new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, fibrodysplasia ossificans progressiva FOP impacts about 400... -Today at 03:33 pm- MarketScreener
Source: marketscreener.com
Ipsen announces European Commission decision on palovarotene for the treatment of FOP
European Commission determines not to grant marketing authorization approval for palovarotene for fibrodysplasia ossificans progressiva Decision follows negative opinion by the Committee for Medicinal...
Source: marketscreener.com
Ipsen announces European Commission decision on
European Commission determines not to grant marketing authorization approval for palovarotene for fibrodysplasia ossificans progressiva (FOP)Decision...
Source: globenewswire.com
Galderma WCD 2023 LateBreaking Phase III Results for Nemolizumab Monotherapy in Prurigo Nodularis Show a Significant Proportion of ItchFree Patients by Week 4
Galderma presented the latest data from its pivotal phase III OLYMPIA 2 trial at the 25th World Congress of Dermatology WCD in Singapore.
Source: businesswireindia.com